Goldman Sachs
ZNTL icon

Goldman Sachs’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Goldman Sachs’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.08M Buy
462,678
+344,466
+291% +$890K ﹤0.01% 5044
2025
Q4 		$160K Sell
118,212
-226,943
-66% -$330K ﹤0.01% 6098
2025
Q3 		$521K Sell
345,155
-516,612
-60% -$774K ﹤0.01% 5487
2025
Q2 		$1,000K Buy
861,767
+405,374
+89% +$535K ﹤0.01% 4703
2025
Q1 		$726K Sell
456,393
-461,714
-50% -$996K ﹤0.01% 4935
2024
Q4 		$2.78M Buy
918,107
+284,043
+45% +$931K ﹤0.01% 4008
2024
Q3 		$2.33M Buy
634,064
+14,811
+2% +$53.8K ﹤0.01% 4016
2024
Q2 		$2.53M Buy
619,253
+287,253
+87% +$3.21M ﹤0.01% 3742
2024
Q1 		$5.23M Buy
332,000
+39,119
+13% +$538K ﹤0.01% 3049
2023
Q4 		$4.44M Buy
292,881
+69,620
+31% +$1.02M ﹤0.01% 3264
2023
Q3 		$4.48M Sell
223,261
-510,316
-70% -$13M ﹤0.01% 3084
2023
Q2 		$20.7M Buy
733,577
+529,631
+260% +$12.7M ﹤0.01% 1816
2023
Q1 		$3.51M Sell
203,946
-186,436
-48% -$3.78M ﹤0.01% 3388
2022
Q4 		$7.86M Buy
390,382
+52,050
+15% +$1.12M ﹤0.01% 2793
2022
Q3 		$7.33M Sell
338,332
-59,238
-15% -$1.62M ﹤0.01% 2801
2022
Q2 		$11.2M Buy
397,570
+132,324
+50% +$3.51M ﹤0.01% 2410
2022
Q1 		$12.2M Buy
265,246
+123,877
+88% +$6.68M ﹤0.01% 2484
2021
Q4 		$11.9M Sell
141,369
-88,972
-39% -$6.88M ﹤0.01% 2602
2021
Q3 		$15.3M Buy
230,341
+146,052
+173% +$8.43M ﹤0.01% 2306
2021
Q2 		$4.48M Buy
84,289
+32,480
+63% +$1.74M ﹤0.01% 3429
2021
Q1 		$2.25M Sell
51,809
-172,174
-77% -$7.41M ﹤0.01% 3876
2020
Q4 		$11.6M Buy
223,983
+191,812
+596% +$8.65M ﹤0.01% 2328
2020
Q3 		$1.05M Buy
32,171
+18,351
+133% +$643K ﹤0.01% 4042
2020
Q2 		$664K Buy
+13,820
New +$530K ﹤0.01% 4219

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Goldman Sachs's ZNTL Position: Q1 2026 in Review

Goldman Sachs increased its Zentalis Pharmaceuticals (ZNTL) stake by 291% in Q1 2026, buying an estimated $890K and bringing the position to 462,678 shares worth $1.08M. The position accounts for ﹤0.01% of the portfolio, ranked #5044.

Goldman Sachs first reported a position in ZNTL in Q2 2020 and has held it in 24 quarters since. The position peaked at $20.7M in Q2 2023. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • Goldman Sachs held 462,678 shares of Zentalis Pharmaceuticals worth $1.08M as of Q1 2026.
  • Goldman Sachs bought 344,466 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $890K.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #5044 holding.
  • Goldman Sachs first reported a position in Zentalis Pharmaceuticals in Q2 2020 and has held it in 24 quarters since.
  • Goldman Sachs's Zentalis Pharmaceuticals position peaked at $20.7M in Q2 2023.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.